查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969270

运动障碍市场：依运动障碍类型、治疗方法、给药途径、患者照护环境和最终使用者划分－2026-2032年全球预测

Dyskinesia Market by Dyskinesia Type, Treatment Type, Route of Administration, Patient Care Settings, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，运动障碍市场价值将达到 36.6 亿美元，到 2026 年将成长至 39.3 亿美元，到 2032 年将达到 61 亿美元，复合年增长率为 7.55%。

主要市场统计数据
基准年 2025 36.6亿美元
预计年份：2026年 39.3亿美元
预测年份 2032 61亿美元
复合年增长率 (%) 7.55%

对运动障碍的引人入胜的介绍：整合了临床定义、患者和看护者的负担、诊断的复杂性、未满足的需求以及研究的必要性。

运动障碍是一组复杂的运动过度症，病因多样，为患者及其看护者带来显着的临床挑战和生活品质（QOL）问题。不同专科对运动障碍的定义与分类各不相同，导致诊断复杂，治疗方案也多元。因此，临床医生必须结合细緻的表型分析和纵向评估，以区分波动性舞蹈症、持续性肌张力不全症姿势和局部肌阵挛等症状。这种多样性要求制定个人化的治疗方案，以平衡症状控制和功能维持。

本文概述了透过治疗创新、数位健康整合、不断发展的支付方框架和监管改革，运动障碍领域正在发生的变革性转变。

近年来，临床实践、治疗研发和医疗技术的变革性变化正在改变我们对运动障碍的理解和治疗方式。神经生理监测和数位表型分析的进步使得运动模式的表征更加精细，从而支持标靶治疗策略和客观疗效评估。同时，新型药理机制和神经调控技术的不断完善，拓展了临床医师可用的治疗手段，使其能够更精准地调控异常运动迴路。

对计划于 2025 年实施的美国关税调整将如何影响医疗设备和药品的供应链、治疗取得以及跨境合作进行严格评估。

影响跨境贸易的政策变化，包括美国将于2025年实施的关税调整，将对整个运动障碍治疗生态系统产生连锁反应，影响医疗设备、专用诊断设备和药品原料的流通。供应链相关人员正在重新审视筹资策略、库存管理政策和供应商关係，以减轻潜在的供应中断。特别是神经调控硬体和输注系统的製造商和经销商，可能需要调整其物流和零件采购策略，以确保向治疗中心和专科诊所的供应持续性。

基于细分的深入分析揭示了每种非自主运动亚型、治疗方法、给药途径和医疗保健环境的不同临床需求和商业策略。

针对特定细分市场的趋势揭示了临床需求和服务设计中的细微模式，这些模式应指南产品开发和护理策略。在按类型细分运动障碍时，手足徐动症、舞蹈症、肌张力不全症相关性运动障碍、肌阵挛性运动障碍、帕金森氏症运动障碍、痉挛性斜颈和迟发性运动障碍各自具有不同的病理学和症状特征，因此需要针对每种类型製定相应的诊断演算法和治疗方法。例如，一种对持续性肌张力不全症姿势有效的治疗方法可能不适用于阵发性舞蹈样运动，临床试验必须在终点和表型选择上考虑这些差异。

一项策略性区域分析，重点分析了美洲、欧洲、中东和非洲以及亚太地区在临床实践、监管管道、报销趋势和服务提供模式方面的差异。

区域特征显着影响临床路径、监管预期和医疗体系的接受度，导致创新采纳环境的差异。儘管美洲的临床实践中以整合的神经病学网络和成熟的医疗设备采纳环境为主导，但不同支付方的报销方案各异，因此需要製定适应性强的商业策略，以在不同的支付方环境下展现价值。区域内的跨境合作有助于临床研究和实践创新成果的快速传播，但相关人员要求持续调整结果指标。

对致力于运动障碍治疗的公司进行业务策略、投资组合优先排序、临床研发管线活动、伙伴关係模式和商业化策略的全面管理分析。

在运动障碍领域，企业行为和动态受投资组合选择、研究优先顺序以及对跨学科合作的投资意愿的影响。领先机构通常奉行平衡策略，将现有疗法的短期优化与对新型作用机制和神经调控技术的长期投资相结合。医疗设备製造商、生物製药开发公司和学术机构之间的策略联盟能够加速转化研究，并使各方共享临床网路资源，从而进行临床试验和上市后监测。

一项切实可行的行动计划，为行业领导者提供优先建议，以加强研发重点、降低供应链风险、改善患者就医途径并协调相关人员的奖励。

产业领导者应优先考虑能够兼顾临床价值、营运韧性和相关人员参与的切实可行的措施。首先，投资于后期临床项目和观察性研究，利用客观的数位生物标记和患者报告结局来证明其在多种运动障碍症状方面具有显着疗效。这将使申办方能够支持医保报销谈判，并建立强有力的证据包，从而促进指南的製定。其次，透过加强供应链策略，实现零件来源多元化和区域製造地扩张，从而确保关键医疗设备和治疗药物的可及性，并降低关税和物流风险。

对调查方法进行透明的解释，包括分析中使用的来源选择、定性和定量整合方法、专家咨询过程和检验通讯协定。

本分析整合了同行评审文献、临床指南、监管指导文件、专家访谈以及汇总的临床项目资讯披露信息，以确保结论具有平衡性和检验。数据选择优先考虑专业学会的最新主要调查和共识声明，并辅以来自神经科、康復专家、医疗设备工程师和支付方顾问的定性信息，以反映实际操作情况和决策标准。此外，还使用了已发表的病例係列和註册数据，以阐明临床异质性和真实世界的治疗模式。

本报告提供了简洁的结论，总结了对临床医生、製造商、支付方、监管机构和患者权益倡导者的战略意义，以及改善运动障碍治疗效果的切实可行的后续步骤。

临床复杂性、不断发展的技术以及不断变化的政策环境揭示了运动障碍的动态发展状态，这既需要有针对性的创新，也需要係统性的调整。临床医生必须利用数位化测量和多学科协作，不断改进基于表型的治疗，并优化治疗效果。同时，研发人员和製造商应使其研发策略与实际的交付限制相符，并投资于能够与现有治疗路径和报销机制相整合的治疗方法和服务模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 运动障碍市场：非自主运动的类型

  • 手足徐动症
  • 舞蹈症
  • 肌张力不全症相关运动障碍
  • 肌阵挛性运动障碍
  • 帕金森氏症运动障碍
  • 痉挛性斜颈
  • 迟发性运动障碍

第九章：依治疗方法分類的运动障碍市场

  • 非药物疗法
    • 行为疗法
    • 物理治疗与復健
  • 药物治疗
    • 抗胆碱能药物
    • 多巴胺调节剂
    • GABA能促效剂
    • NMDA受体拮抗剂
    • VMAT2抑制剂
  • 手术治疗方法
    • 切除手术
    • 深部脑部刺激（DBS）

第十章：运动障碍药物市场：依给药途径划分

  • 静脉注射（IV）和输液
  • 口服
  • 皮下注射
  • 经皮

第十一章患者照护环境分類的运动障碍市场

  • 居家照护
  • 医院
  • 研究机构
  • 专科诊所及復健中心

第十二章 运动障碍市场：依最终使用者划分

  • 居家医疗环境
  • 医院和诊所
    • 住院服务
    • 门诊医疗服务
  • 长期照护机构
  • 运动障碍专科中心

第十三章 运动障碍市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：运动障碍市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 运动障碍市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国运动障碍市场

第十七章：中国运动障碍市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics BV
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-535C6291879B

The Dyskinesia Market was valued at USD 3.66 billion in 2025 and is projected to grow to USD 3.93 billion in 2026, with a CAGR of 7.55%, reaching USD 6.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.66 billion
Estimated Year [2026] USD 3.93 billion
Forecast Year [2032] USD 6.10 billion
CAGR (%) 7.55%

A compelling introduction to dyskinesia that synthesizes clinical definitions, patient and caregiver burden, diagnostic complexity, unmet needs, and research imperatives

Dyskinesia encompasses a complex set of hyperkinetic movement disorders that arise from diverse etiologies and present significant clinical and quality-of-life challenges for patients and caregivers. Definitions and classifications vary across specialties, which contributes to diagnostic complexity and heterogeneous treatment pathways. Consequently, clinicians must combine careful phenotyping with longitudinal assessment to distinguish among presentations such as fluctuating chorea, sustained dystonic postures, or focal myoclonic jerks. This heterogeneity drives the need for individualized care plans that balance symptomatic control with preservation of function.

Beyond clinical heterogeneity, dyskinesia imposes substantial psychosocial and functional burdens that ripple across families and health systems. Patients frequently face impaired mobility, communication difficulties, social isolation, and reduced employment opportunities, while caregivers manage escalating demands for supervision and rehabilitation. These realities underline the necessity for integrated care models that coordinate neurology, rehabilitation, and mental health services. Moving forward, stakeholders increasingly prioritize interventions that address both motor symptoms and associated nonmotor sequelae, and they emphasize patient-centered outcome measures to capture meaningful change across the disease trajectory.

An outline of transformative shifts reshaping the dyskinesia landscape through therapeutic innovation, digital health integration, evolving payer frameworks, and regulatory reform

Recent years have seen transformative shifts across clinical practice, therapeutic development, and health technology that are reshaping how dyskinesia is understood and managed. Advances in neurophysiological monitoring and digital phenotyping enable more granular characterization of movement patterns, which in turn supports targeted therapeutic strategies and objective outcome measurement. In parallel, novel pharmacological mechanisms and refinements in neuromodulation expand the therapeutic toolkit available to clinicians, allowing more precise modulation of aberrant motor circuits.

At the same time, digital health integration and remote-monitoring platforms are changing care delivery by facilitating continuous symptom tracking, medication adherence support, and virtual rehabilitation. These technologies accelerate iterative learning in clinical programs and open new pathways for decentralized trials. Regulatory landscapes and payer expectations are also evolving; stakeholders increasingly demand real-world evidence and patient-reported outcomes to validate clinical benefit. Consequently, collaborations across industry, academia, and clinical networks are becoming central to advancing translational research and aligning product development with practical implementation needs.

A rigorous assessment of how United States tariff changes slated for 2025 could alter medical device and pharmaceutical supply chains, access to therapies, and cross-border collaborations

Policy changes that affect cross-border trade, including tariff adjustments implemented by the United States in 2025, have implications across the dyskinesia ecosystem by influencing the flow of medical devices, specialized diagnostic equipment, and pharmaceutical inputs. Supply chain stakeholders are reassessing sourcing strategies, inventory policies, and vendor relationships to mitigate potential disruptions. In particular, manufacturers and distributors of neuromodulation hardware and infusion systems may need to re-examine logistics and component sourcing to preserve continuity of supply to treatment centers and specialty clinics.

In addition, clinical research programs that rely on global collaboration and device transfer face more complex operational requirements when tariffs alter the economics of shipping and local manufacturing. Procurement teams within hospitals, specialty centers, and long-term care facilities must adapt contracting and purchasing cycles to maintain access to essential therapies. In response, many organizations are intensifying supplier diversification, increasing regional manufacturing partnerships, and exploring alternative distribution models to retain resilience. These near-term adjustments are likely to influence longer-term commercial planning and partnership structures across the therapeutic landscape.

A focused analysis of segmentation-driven insights that illuminate differential clinical needs and commercial strategies across dyskinesia subtypes, treatment types, administration routes, and care settings

Segment-specific dynamics reveal nuanced patterns of clinical need and service design that should inform product development and care strategies. When considering dyskinesia type segmentation, distinct pathophysiologies and symptom profiles characterize Athetosis, Chorea, Dystonia-Related Dyskinesia, Myoclonic Dyskinesia, Parkinson's Dyskinesia, Spasmodic Torticollis, and Tardive Dyskinesia, each demanding tailored diagnostic algorithms and therapeutic approaches. For example, treatments that effectively address sustained dystonic postures may not translate to paroxysmal choreiform movements, and clinical trials must account for these differences in endpoint selection and phenotypic enrichment.

Looking across treatment type segmentation, non-pharmacological approaches such as behavioral therapy and physical therapy & rehabilitation play foundational roles in functional restoration, while pharmacological treatments deliver symptomatic modulation through anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, and VMAT2 inhibitors. Surgical options remain critical for refractory cases, and ablative surgery and deep brain stimulation (DBS) offer distinct risk-benefit profiles that clinicians weigh against symptom severity and patient goals. Route of administration segmentation underscores how intravenous and infusion-based therapies, oral agents, subcutaneous formulations, and transdermal systems create different adherence, monitoring, and delivery considerations, particularly for patients in homecare settings.

Patient care settings and end-user segmentation further shape commercialization and service models. Home care, hospitals, research institutes, and specialty clinics & rehabilitation centers each require unique training, monitoring, and equipment. End users such as homecare settings, hospitals & clinics with both inpatient and outpatient services, long-term care facilities, and specialty movement disorder centers show variable capacity for advanced therapies and multidisciplinary management. Integrating these segmentation insights enables more targeted clinical development, reimbursement strategies, and implementation roadmaps that reflect real-world constraints and opportunities.

A strategic regional analysis that highlights clinical practice variation, regulatory pathways, reimbursement dynamics, and service delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific landscapes

Regional characteristics exert meaningful influence on clinical pathways, regulatory expectations, and health system capacity, creating differentiated environments for innovation adoption. In the Americas, clinical practice patterns emphasize integrated neurology networks and a mature device adoption landscape, yet reimbursement heterogeneity across payers requires adaptive commercial strategies that can demonstrate value in diverse payer contexts. Cross-border collaboration within the region supports clinical research and rapid dissemination of practice innovations, but stakeholders must continuously align on standards for outcome measurement.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement models vary widely, with some countries demonstrating strong centralized HTA processes and others relying on local hospital-level decision-making. These differences affect timing of access and the types of evidence that are persuasive to payers and providers. Meanwhile, Asia-Pacific features a mix of rapidly advancing clinical infrastructure and high-capacity centers alongside regions where access to specialized therapies remains constrained. As a result, regional partnerships, local manufacturing options, and culturally adapted care models play a key role in expanding access to advanced treatments. Taken together, geographic nuances underscore the importance of regionally tailored clinical development plans, regulatory strategies, and stakeholder engagement frameworks to ensure sustainable implementation of dyskinesia innovations.

An executive synthesis of corporate strategies, portfolio prioritization, clinical pipeline activity, partnership models, and commercialization tactics among firms shaping dyskinesia care

Corporate behavior and competitive dynamics in dyskinesia are shaped by portfolio choices, research prioritization, and the willingness to invest in multidisciplinary collaborations. Leading organizations often pursue balanced strategies that combine near-term optimization of existing therapies with longer-term investments in novel mechanisms and neuromodulation technologies. Strategic partnerships between device manufacturers, biopharmaceutical developers, and academic centers accelerate translational work and enable shared access to clinical networks for trials and post-market studies.

Commercial differentiation increasingly hinges on integrated service offerings that pair therapeutic modalities with digital monitoring, patient support programs, and data-driven outcomes measurement. Companies that develop robust real-world evidence programs and cultivate strong relations with specialty movement disorder centers and payer stakeholders are better positioned to articulate value propositions and streamline adoption. Additionally, supply chain resilience and regulatory expertise remain important competitive levers; organizations investing in diversified sourcing, local manufacturing partnerships, and proactive regulatory engagement can reduce operational risk while improving time-to-care for patients in fragmented health system environments.

A pragmatic action plan offering prioritized recommendations for industry leaders to strengthen R&D focus, de-risk supply networks, improve patient pathways, and align stakeholder incentives

Industry leaders should prioritize a set of actionable initiatives that align clinical value with operational resilience and stakeholder engagement. First, invest in late-stage clinical programs and observational studies that employ objective digital biomarkers and patient-reported outcomes to demonstrate meaningful benefit across heterogeneous dyskinesia presentations. By doing so, sponsors can build persuasive evidence packages that support reimbursement discussions and inform guideline development. Second, strengthen supply chain strategies by diversifying component sourcing and expanding regional manufacturing options to mitigate tariff-related and logistical risks, thereby preserving access to critical devices and therapeutics.

Third, embed care delivery innovations by partnering with specialty centers, homecare providers, and rehabilitation networks to create integrated pathways that combine pharmacology, surgical options, and rehabilitative support. Such partnerships should include training initiatives to ensure consistent quality of care and proper utilization of advanced therapies. Fourth, accelerate commercial readiness by designing flexible pricing and contracting models that reflect heterogeneity across payers and providers, coupled with real-world evidence commitments to demonstrate sustained value. Finally, foster collaborative research ecosystems by aligning with academic consortia and patient advocacy organizations to co-develop outcome measures, improve trial recruitment, and ensure that product development remains responsive to lived experience and clinical priorities.

A transparent research methodology description covering source selection, qualitative and quantitative synthesis methods, expert consultation processes, and validation protocols used in the analysis

This analysis synthesizes evidence from peer-reviewed literature, clinical guidelines, regulatory guidance documents, expert interviews, and aggregated clinical program disclosures to ensure a balanced and verifiable foundation for conclusions. Data selection prioritized recent primary research and consensus statements from specialty societies, complemented by qualitative inputs from neurologists, rehabilitation specialists, device engineers, and payer advisors to capture operational realities and decision-making criteria. In addition, published case series and registry data were used to contextualize clinical heterogeneity and real-world treatment patterns.

The review applied structured evidence synthesis techniques, combining thematic qualitative analysis with cross-validation from subject-matter experts to identify convergent insights and areas of uncertainty. Validation protocols included triangulating clinical assertions against guideline recommendations and soliciting feedback from external clinicians who manage complex dyskinesia cases. Throughout the process, transparency and reproducibility were emphasized by documenting source provenance and methodological choices, while acknowledging limitations where evidence gaps remain. This approach supports credible interpretation of the landscape and informs practical recommendations for stakeholders.

A concise conclusion that distills strategic implications for clinicians, manufacturers, payers, regulators, and patient advocates and outlines pragmatic next steps to improve dyskinesia outcomes

Synthesizing clinical complexity, evolving technologies, and shifting policy contexts reveals a dynamic dyskinesia landscape in which targeted innovation and system-level adaptation are both required. Clinicians must continue to refine phenotype-driven care, leveraging digital measurement and multidisciplinary collaboration to optimize outcomes. At the same time, developers and manufacturers should align development strategies with practical delivery constraints, investing in therapies and service models that integrate with existing care pathways and reimbursement realities.

Policymakers and purchasers can accelerate meaningful access by recognizing the heterogeneity of dyskinesia presentations and by supporting flexible evidence paradigms that reward functional improvements and patient-centered outcomes. Finally, cross-sector collaboration-linking academic research, clinical centers, industry, and patient advocacy-remains essential to close evidence gaps and scale high-impact interventions. Taken together, these strategic implications point to a coordinated agenda that balances innovation with implementability to improve care for individuals affected by dyskinesia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dyskinesia Market, by Dyskinesia Type

  • 8.1. Athetosis
  • 8.2. Chorea
  • 8.3. Dystonia-Related Dyskinesia
  • 8.4. Myoclonic Dyskinesia
  • 8.5. Parkinson's Dyskinesia
  • 8.6. Spasmodic Torticollis
  • 8.7. Tardive Dyskinesia

9. Dyskinesia Market, by Treatment Type

  • 9.1. Non-Pharmacological Approaches
    • 9.1.1. Behavioral Therapy
    • 9.1.2. Physical Therapy & Rehabilitation
  • 9.2. Pharmacological Treatments
    • 9.2.1. Anticholinergics
    • 9.2.2. Dopamine Modulators
    • 9.2.3. GABA Agonists
    • 9.2.4. NMDA Receptor Antagonists
    • 9.2.5. VMAT2 Inhibitors
  • 9.3. Surgical Treatments
    • 9.3.1. Ablative Surgery
    • 9.3.2. Deep Brain Stimulation (DBS)

10. Dyskinesia Market, by Route of Administration

  • 10.1. Intravenous (IV) & Infusion-Based
  • 10.2. Oral
  • 10.3. Subcutaneous
  • 10.4. Transdermal

11. Dyskinesia Market, by Patient Care Settings

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics & Rehabilitation Centers

12. Dyskinesia Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals & Clinics
    • 12.2.1. Inpatient Services
    • 12.2.2. Outpatient Services
  • 12.3. Long-Term Care Facilities
  • 12.4. Specialty Movement Disorder Centers

13. Dyskinesia Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dyskinesia Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dyskinesia Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dyskinesia Market

17. China Dyskinesia Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Addex Therapeutics Ltd.
  • 18.8. Bukwang Pharmaceutical Co., Ltd
  • 18.9. Clearmind Medicine Inc.
  • 18.10. Ipsen Pharma SAS
  • 18.11. IRLAB Therapeutics AB
  • 18.12. Luye Pharma Group Ltd.
  • 18.13. Medtronic PLC
  • 18.14. Melior Pharmaceuticals
  • 18.15. Mitsubishi Tanabe Pharma Corporation
  • 18.16. Motac France Sarl
  • 18.17. Neurocrine Biosciences, Inc.
  • 18.18. Neurolixis Inc.
  • 18.19. PharmaTher Holdings Ltd.
  • 18.20. Prilenia Therapeutics B.V.
  • 18.21. ReCode Therapeutics, Inc.
  • 18.22. Serina Therapeutics, Inc.
  • 18.23. SOM INNOVATION BIOTECH, SA
  • 18.24. Supernus Pharmaceuticals, Inc.
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. Toray Industries, Inc.
  • 18.27. Vistagen Therapeutics, Inc.
  • 18.28. Voyager Therapeutics, Inc.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. G7 DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. NATO DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)